162 related articles for article (PubMed ID: 11896977)
1. Randomized trial of topically applied repifermin (recombinant human keratinocyte growth factor-2) to accelerate wound healing in venous ulcers.
Robson MC; Phillips TJ; Falanga V; Odenheimer DJ; Parish LC; Jensen JL; Steed DL
Wound Repair Regen; 2001; 9(5):347-52. PubMed ID: 11896977
[TBL] [Abstract][Full Text] [Related]
2. Randomized trial and local biological effect of autologous platelets used as adjuvant therapy for chronic venous leg ulcers.
Senet P; Bon FX; Benbunan M; Bussel A; Traineau R; Calvo F; Dubertret L; Dosquet C
J Vasc Surg; 2003 Dec; 38(6):1342-8. PubMed ID: 14681639
[TBL] [Abstract][Full Text] [Related]
3. Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trial.
Sandborn WJ; Sands BE; Wolf DC; Valentine JF; Safdi M; Katz S; Isaacs KL; Wruble LD; Katz J; Present DH; Loftus EV; Graeme-Cook F; Odenheimer DJ; Hanauer SB
Aliment Pharmacol Ther; 2003 Jun; 17(11):1355-64. PubMed ID: 12786629
[TBL] [Abstract][Full Text] [Related]
4. The influence of patient and wound variables on healing of venous leg ulcers in a randomized controlled trial of growth-arrested allogeneic keratinocytes and fibroblasts.
Lantis JC; Marston WA; Farber A; Kirsner RS; Zhang Y; Lee TD; Cargill DI; Slade HB
J Vasc Surg; 2013 Aug; 58(2):433-9. PubMed ID: 23588112
[TBL] [Abstract][Full Text] [Related]
5. The effect of thymosin treatment of venous ulcers.
Guarnera G; DeRosa A; Camerini R;
Ann N Y Acad Sci; 2010 Apr; 1194():207-12. PubMed ID: 20536470
[TBL] [Abstract][Full Text] [Related]
6. Phase I/II randomized trial evaluating the safety and clinical effects of repifermin administered to reduce mucositis in patients undergoing autologous hematopoietic stem cell transplantation.
Freytes CO; Ratanatharathorn V; Taylor C; Abboud C; Chesser N; Restrepo A; Arango J; Odenheimer D
Clin Cancer Res; 2004 Dec; 10(24):8318-24. PubMed ID: 15623608
[TBL] [Abstract][Full Text] [Related]
7. Recombinant human granulocyte-macrophage colony-stimulating factor applied locally in low doses enhances healing and prevents recurrence of chronic venous ulcers.
Jaschke E; Zabernigg A; Gattringer C
Int J Dermatol; 1999 May; 38(5):380-6. PubMed ID: 10369552
[TBL] [Abstract][Full Text] [Related]
8. Topical use of human recombinant epidermal growth factor (h-EGF) in venous ulcers.
Falanga V; Eaglstein WH; Bucalo B; Katz MH; Harris B; Carson P
J Dermatol Surg Oncol; 1992 Jul; 18(7):604-6. PubMed ID: 1624634
[TBL] [Abstract][Full Text] [Related]
9. Treatment of venous ulcers with pentoxifylline: a 12-month, double-blind, placebo controlled trial. Microcirculation and healing.
De Sanctis MT; Belcaro G; Cesarone MR; Ippolito E; Nicolaides AN; Incandela L; Geroulakos G
Angiology; 2002; 53 Suppl 1():S49-51. PubMed ID: 11865837
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo effects of repifermin (keratinocyte growth factor-2, KGF-2) on human carcinoma cells.
Alderson R; Gohari-Fritsch S; Olsen H; Roschke V; Vance C; Connolly K
Cancer Chemother Pharmacol; 2002 Sep; 50(3):202-12. PubMed ID: 12203102
[TBL] [Abstract][Full Text] [Related]
11. Systemic treatment of venous leg ulcers with high doses of pentoxifylline: efficacy in a randomized, placebo-controlled trial.
Falanga V; Fujitani RM; Diaz C; Hunter G; Jorizzo J; Lawrence PF; Lee BY; Menzoian JO; Tretbar LL; Holloway GA; Hoballah J; Seabrook GR; McMillan DE; Wolf W
Wound Repair Regen; 1999; 7(4):208-13. PubMed ID: 10781212
[TBL] [Abstract][Full Text] [Related]
12. The effect of amelogenins (Xelma) on hard-to-heal venous leg ulcers.
Vowden P; Romanelli M; Peter R; Boström A; Josefsson A; Stege H
Wound Repair Regen; 2006; 14(3):240-6. PubMed ID: 16808801
[TBL] [Abstract][Full Text] [Related]
13. Treatment of venous ulcers with pentoxifylline: a 6-month randomized, double-blind, placebo controlled trial.
Belcaro G; Cesarone MR; Nicolaides AN; De Sanctis MT; Incandela L; Geroulakos G
Angiology; 2002; 53 Suppl 1():S45-7. PubMed ID: 11865836
[TBL] [Abstract][Full Text] [Related]
14. Topical treatment of chronic venous ulcers with sucralfate: a placebo controlled randomized study.
Tumino G; Masuelli L; Bei R; Simonelli L; Santoro A; Francipane S
Int J Mol Med; 2008 Jul; 22(1):17-23. PubMed ID: 18575771
[TBL] [Abstract][Full Text] [Related]
15. Double-blind placebo-controlled study with topical 2% ketanserin ointment in the treatment of venous ulcers.
Roelens P
Dermatologica; 1989; 178(2):98-102. PubMed ID: 2647535
[TBL] [Abstract][Full Text] [Related]
16. Simvastatin as a novel therapeutic agent for venous ulcers: a randomized, double-blind, placebo-controlled trial.
Evangelista MT; Casintahan MF; Villafuerte LL
Br J Dermatol; 2014 May; 170(5):1151-7. PubMed ID: 24506834
[TBL] [Abstract][Full Text] [Related]
17. Pharmacologic and pharmacokinetic profile of repifermin (KGF-2) in monkeys and comparative pharmacokinetics in humans.
Sung C; Parry TJ; Riccobene TA; Mahoney A; Roschke V; Murray J; Gu ML; Glenn JK; Caputo F; Farman C; Odenheimer DJ
AAPS PharmSci; 2002; 4(2):E8. PubMed ID: 12102617
[TBL] [Abstract][Full Text] [Related]
18. Topical epidermal growth factor spray for the treatment of chronic diabetic foot ulcers: A phase III multicenter, double-blind, randomized, placebo-controlled trial.
Park KH; Han SH; Hong JP; Han SK; Lee DH; Kim BS; Ahn JH; Lee JW
Diabetes Res Clin Pract; 2018 Aug; 142():335-344. PubMed ID: 29902542
[TBL] [Abstract][Full Text] [Related]
19. Chronic venous leg ulcers: is topical zinc the answer? A review of the literature.
O'Connor S; Murphy S
Adv Skin Wound Care; 2014 Jan; 27(1):35-44; quiz 45-6. PubMed ID: 24343392
[TBL] [Abstract][Full Text] [Related]
20. [Questionable effectiveness of autologous platelet growth factors (PDWHF) in treatment of venous ulcers of the leg].
Reutter H; Bort S; Jung MF; Klyscz T; Schippert W; Zuder D; Jünger M
Hautarzt; 1999 Dec; 50(12):859-65. PubMed ID: 10663020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
